Stay updated on Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page
- CheckyesterdayChange DetectedA site-wide funding-status notice was added and the page revision updated from v3.4.0 to v3.4.1.SummaryDifference0.6%

- Check8 days agoChange DetectedUI changes to the history view include a glossary toggle, green highlights for additions, red highlights for deletions, and visible revision/version labeling. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedA new site revision (v3.3.4) was added, replacing the previous revision (v3.3.3). This change affects page metadata and does not modify trial data, status, or details.SummaryDifference0.1%

- Check43 days agoChange DetectedThe changes consist of adding Revision: v3.3.3 and removing HHS Vulnerability Disclosure and Revision: v3.3.2 from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check72 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; the update appears to be a platform/UI change with no changes to the study records or history data.SummaryDifference0.1%

- Check79 days agoChange DetectedRemoved the government funding and operating status notice from the page.SummaryDifference0.5%

Stay in the know with updates to Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page.